Cipla-NiPPharma In Respiratory Device Deal?
Executive Summary
Cipla Ltd. is speculated to have struck a deal with Japan's NiPPharma Co., Ltd for a device apparently meant for the Indian firm's generic Advair dry powder inhaler (DPI) but some analysts suggest that limited visibility around the trials of the firm's salmeterol + fluticasone combination in the US stay a concern for now.
You may also be interested in...
What’s On CEO Andrew Witty’s To-Do List Before Exiting GSK
The company showed signs of stabilization in the first quarter, as Witty insisted his diversified strategy is beginning to pay off. But a new CEO will have to contend with the potential entry of Advair generics.
Mylan's Generic Advair FDA Filing Puts Added Squeeze On GSK
The increasing urgency for GlaxoSmithKline PLC to build up its overall respiratory portfolio was underscored when Mylan NV confirmed it has submitted an abbreviated new drug application (ANDA) to the FDA for launch of the first generic alternative to GSK's top-selling Seretide Evohaler (salmeterol xinafoate + fluticasone propionate), known in the US as Advair Diskus.
Transformative Innovation: How India Can Up Its Game, Big Pharma GCCs Add Value
A new report discusses the priorities that India should focus on to leapfrog towards transformative innovation. Big pharma’s expanding global capability centres (GCCs) in India are also contributing to the innovation ecosystem while positioning the country as the global industry's “backbone”.